Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. director and co-founder Jonathan Sheena reported indirect open-market sales of common stock by family trusts associated with him. The trusts sold a total of 1,500 shares on April 17, 2026 in two transactions at weighted average prices of about $199.59 and $199.66 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed by the Caraluna 1 and Caraluna 2 Trusts, which hold the shares for trust beneficiaries, and Sheena disclaims beneficial ownership of those securities. Following these transactions, the filing shows 259,255 Natera shares held directly by Sheena and 20,282 shares reported as held indirectly through each trust.
Natera, Inc. filed an initial insider ownership statement for Eric H. Rubin
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options and used shares to cover taxes. He exercised options to acquire 58,292 shares of Common Stock at an exercise price of $9.59 per share. To satisfy tax obligations, 27,610 shares of Common Stock were withheld at $204.87 per share. Following these transactions, he held 2,383,162 shares of Common Stock directly, plus 5,000 shares held indirectly by his spouse.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, conducted open-market sales of company common stock. On April 1, 2026, he sold a total of 8,400 shares at weighted average prices within disclosed ranges between $200.47 and $205.50 per share under a pre-arranged Rule 10b5-1 trading plan. Following these sales, he continued to hold 224,885 shares of Natera common stock directly.
Natera, Inc. executive Solomon Moshkevich reported selling 3,000 shares of Common Stock in open-market transactions. On April 1, 2026, he executed three sales of 1,048, 1,000, and 952 shares at weighted average prices of $201.3206, $202.3638, and $203.3106 per share.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating they were scheduled in advance. After these transactions, Moshkevich directly owns 147,882 shares of Natera common stock.
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options to acquire 41,708 shares of Common Stock. He exercised a fully exercisable option with a strike price of $9.59 per share, converting it into 41,708 Common shares on a one-for-one basis.
Following the transaction, he directly holds 2,352,480 shares of Natera Common Stock and 58,292 stock options. In addition, 5,000 Common shares are reported as indirectly owned by his spouse.
Natera, Inc. expanded its Board of Directors from ten to eleven members and appointed Eric Rubin as a Class I director, effective March 26, 2026. His initial term runs until the 2028 annual meeting of stockholders, and the Board has deemed him an independent director under Nasdaq standards.
Dr. Rubin will serve on the Board’s Nominating, Corporate Governance and Compliance Committee and receive cash and equity pay consistent with other non-employee directors under Natera’s Amended Compensation Program for Non-Employee Directors. His initial equity award will vest in three equal installments on March 26, 2027, 2028 and 2029.
The company also entered into an Indemnification Agreement with Dr. Rubin, providing indemnification and advancement of expenses to the fullest extent permitted by law for claims related to his service. There are no family relationships or related-party transactions requiring disclosure in connection with his appointment.
Solomon Moshkevich filed a Form 144 notice indicating planned sales of 3,000 Performance Shares dated 01/14/2026. The filing lists multiple completed common‑share transactions by the same reporting person during early 2026, including a 23,205‑share sale on 01/20/2026 for $5,447,104.57.
Natera Inc — Schedule 13G/A (Amendment No. 7): The Vanguard Group reports no beneficial ownership. The filing states 0 shares beneficially owned, representing 0% of the class as disclosed in the amendment. The filing explains an internal realignment effective January 12, 2026, causing separate reporting by certain Vanguard subsidiaries.
Natera, Inc. director and co-founder Jonathan Sheena reported open-market sales totaling 4,570 shares of common stock. On March 18 and March 20, 2026, shares were sold at prices generally around $196 to $201 per share through multiple transactions.
A portion of the sales was made from direct holdings, leaving 259,255 shares held directly afterward. Additional sales were conducted by Caraluna 1 Trust and Caraluna 2 Trust, which together held 21,032 shares each after the transactions, and are described as held for the benefit of trust beneficiaries, with Sheena disclaiming beneficial ownership.
Footnotes state that the sales were executed under pre-arranged Rule 10b5-1 trading plans adopted on June 7, 2024 and December 11, 2024, indicating the timing was set in advance.